ReviewExperimental eye research2021
Foundational concepts in the biology of bacterial keratitis.
Review in Experimental eye research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 68 citations in OpenAlex.
- Mesenchymal stem cell-derived conditioned medium demonstrates novel antibacterial effects in ocular bacterial infections.Infection and immunity · 2026Article
- Infectious Keratitis: A Retrospective Analysis of a Tertiary Care Center.Journal of clinical medicine · 2026Article
- Enhanced Efficacy of Cefiderocol With PolyTrim Combination Therapy in a Rabbit Model of Extensively Drug-Resistant Pseudomonas aeruginosa Keratitis.Investigative ophthalmology & visual science · 2026Article
- An eye drop combination for treating Staphylococcus aureus-induced keratitis in rats: repurposing ibuprofen.Scientific reports · 2026Article
- What We Can Do in Infectious Keratitis, Except for Conventional Antimicrobial-Based Therapies: Major Narrative Review.Health science reports · 2026Article
- Vaccines for microbial eye diseases in the era of data science: opportunities and challenges.Frontiers in immunology · 2026Review
- Cefiderocol and Moxifloxacin Have Additive and Synergistic Activity Against Pseudomonas aeruginosa Including an Isolate of the 2023 Keratitis Outbreak.Investigative ophthalmology & visual science · 2025Article
- Pathogenesis and treatment strategies for infectious keratitis: Exploring antibiotics, antimicrobial peptides, nanotechnology, and emerging therapies.Journal of pharmaceutical analysis · 2025Review
- Zwitterionic chitosan-modified amorphous ZnCuAl-LDH eye drops for efficient treatment of bacterial keratitis.Materials today. Bio · 2025Article
- Wearing bacteriophages individually with an adhesive drug-loadable nanohelmet for treating ocular infections.Science advances · 2025Article
- Probiotics in Nanotechnology-Driven Wound Healing: From Mechanistic Insight to Clinical Promise.Pharmaceutics · 2025Review
- Aetiology and antibiotic susceptibility of bacterial keratitis at a referral centre in southern Sweden.Scientific reports · 2025Article
- Clinical characteristics and managements of severe corneal ulcers in patients with end-stage glaucoma.International ophthalmology · 2025Article
- Streptococcus pneumoniae keratitis: epidemiology and outcomes over 6 years in a French eye care center.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- An exploration of the ocular mysteries linking nanoparticles to the patho-therapeutic effects against keratitis.Journal of nanobiotechnology · 2025Review
- Research progress on the correlation between corneal neovascularization and lymphangiogenesis (Review).Molecular medicine reports · 2025Review
- Anatomic Biomarkers Predict Poor Presenting Visual Acuity in Infectious Keratitis.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Predisposing factors, clinical and microbiological insights of bacterial keratitis: analysis of 354 cases from a leading French academic centre.The British journal of ophthalmology · 2024Article
- Risk Factors, Clinical Characteristics, and Antibiotic Susceptibility Patterns ofAntibiotics (Basel, Switzerland) · 2024Article
- Advancements in Hydrogels for Corneal Healing and Tissue Engineering.Gels (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Bacterial infections of the cornea, or bacterial keratitis (BK), are notorious for causing rapidly fulminant disease and permanent vision loss, even among treated patients. In the last sixty years, dramatic upward trajectories in the frequency of BK have been observed internationally, driven in large part by the commercialization of hydrogel contact lenses in the late 1960s. Despite this worsening burden of disease, current evidence-based therapies for BK - including broad-spectrum topical antibiotics and, if indicated, topical corticosteroids - fail to salvage vision in a substantial proportion of affected patients. Amid growing concerns of rapidly diminishing antibiotic utility, there has been renewed interest in urgently needed novel treatments that may improve clinical outcomes on an individual and public health level. Bridging the translational gap in the care of BK requires the identification of new therapeutic targets and rational treatment design, but neither of these aims can be achieved without understanding the complex biological processes that determine how bacterial corneal infections arise, progress, and resolve. In this chapter, we synthesize the current wealth of human and animal experimental data that now inform our understanding of basic BK pathophysiology, in context with modern concepts in ocular immunology and microbiology. By identifying the key molecular determinants of clinical disease, we explore how novel treatments can be developed and translated into routine patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.